Boehringer looks to oncology vaccines with €325m acquisition
Boehringer takes on AMAL to gain access to its cancer vaccine technology, with a lead candidate due to enter first-in-human studies this month.
Top Headlines
Global Industry News
-
Symbio and OmniComm expand on current partnership, sign five-year contract
from Outsourcing-Pharma.com
-
AI-enabled platform secures $121m to 'spearhead' NCE discovery, predictive pharmacology
from Outsourcing-Pharma.com
-
Gilead signs 10-year, $5.1bn partnership with Galapagos
from in-PharmaTechnologist.com
-
Warning letter and Form 483 received by Indoco made public
from in-PharmaTechnologist.com
